IMRX

- Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer patients - NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a poster will be presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 4-8, 2026, in Phoenix, AZ, demonstrating that atebimetinib enhances PD-1 checkpoint blockade in RAS mutant tumor models. These findings support Immuneering's plans to conduct a Phase 2 study of atebimetinib in combination with PD-1 blockade in patients with lung cancer.

- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study -

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a trial in progress abstract featuring the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) for the treatment of first-line pancreatic cancer (NCT07562152) has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

- Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months - - New analyses evaluate the overall survival implications of both preserving body mass and reducing tumor volume - NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development taking place September 25-28, 2026, in San Diego, CA.

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management plans to participate in the following upcoming investor conferences: Cantor Global Healthcare Conference (September 9-11 in New York City) Format: Fireside Chat and 1x1 Investor Meetings Date/Time: Thursday, September 10, 2026, from 2:45-3:15 pm ET H.C.

- For patients with second-line (2L) metastatic pancreatic cancer, today's FDA approval of a new treatment is an important milestone –  - For patients with first-line (1L) metastatic pancreatic cancer, Immuneering's atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 – - 17.3-month median overall survival previously reported from Immuneering's Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer - - In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both chemotherapy-related - NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today shared comments following the recent FDA approval of a new second-line pancreatic cancer treatment. “Approval of this new treatment is good news for the subset of pancreatic cancer patients who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy,” said Ben Zeskind, Ph.D.

- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on June 1 -  - Phase 3 MAPKeeper 301 trial is underway, with patients being dosed and over 30 study locations posted to date - - Peer-reviewed publication in Cancer Research details atebimetinib's broad, durable preclinical activity, and favorable tolerability across RAS- and RAF-mutant tumors, along with preservation of body mass - - Ended Q2 2026 with $182.7 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 - NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the second quarter ended June 30, 2026, and provided business updates. “At a time when first-line pancreatic cancer patients finally have treatment options, the 17.3 month median overall survival reported at ASCO for atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in our single-arm Phase 2a study stands out as potentially best-in-class.

- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK inhibitors -

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew Gengos was named Chief Financial Officer of the Company, effective as of July 16, 2026 (the “Start Date”). In connection with the commencement of Mr.

Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).